E. Tomas et al., COMPARISON BETWEEN THE EFFECTS OF TAMOXIFEN AND TOREMIFENE ON THE UTERUS IN POSTMENOPAUSAL BREAST-CANCER PATIENTS, Gynecologic oncology, 59(2), 1995, pp. 261-266
Antiestrogens have been widely used in the treatment of breast cancer
patients. We wanted to compare the uteral and vaginal effects of tamox
ifen to those of toremifene. Thirty-one gynecologically asymptomatic p
ostmenopausal breast cancer patients with an intact uterus were random
ized to receive 20 mg of tamoxifen (N = 16) or 60 mg of toremifene (N
= 15) as an adjuvant treatment. Gynecological examination with vaginal
ultrasonography, Pap smear, endometrial biopsy, hysteroscopy, and cur
ettage was performed before the treatment, and at 6 and 12 months of t
reatment. Endometrial thickness was found to increase significantly du
ring the treatment to the same extent in both groups. Proliferation or
other estrogenic effects in the endometrium were observed in 8 of 14
patients in the tamoxifen group and in 3 of 10 patients in the toremif
ene group. Three polyps occurred and previously present uterine fibroi
ds increased in size in 3 of 10 patients during the study. Estrogenic
changes in Pap smear were observed in all patients. There was no signi
ficant difference between tamoxifen and toremifene in any of the param
eters investigated. Our results suggest that tamoxifen and toremifene
produce comparable estrogenic effects in the uterus and vagina. (C) 19
95 Academic Press, Inc.